Opto Circuits (India) share news and announcements
BSE: 532391Healthcare Equipment & Supplies
Trading suspended since 24 May 2022
Last traded ₹1.80 on 23 May 2022
Opto Circuits (India) share news and announcements
766 announcements, routine notices left out, newest first. Page 16 of 16.
Jul 2007
3 Jul · Utilisation of Funds
Utilisation of Public Issue Proceeds. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.2 Jul · Meeting
Following items were approved by the Shareholders of the Company at their Extra ordinary General Meeting held on June 29, 2007. (1) Issue upto 12,00,000 Convertible Share Warrants on preferential basis to Promoters and Directors of the Subsidiary Companies. (2) Issue upto 12,00,000 Equity shares on preferential basis to FIIs and NRI.
Jun 2007
29 Jun · Dividend
Board of Directors at its meeting held on June 29, 2007 have recommended 50% Dividend for the year 2006-2007 and also One Equity Bonus Shares for every Two fully paid Equity Shares, subject to the approval of the Shareholders in the General Meeting.27 Jun · Corrigendum
Corrigendum published in the Newspaper on June 27, 2007 regarding the Notice of the Extra ordinary General Meeting of the Company to be held on June 29, 2007. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.12 Jun · Board meeting
Inter alia to consider the Audited Financial results of the Company for the year ended March 31, 2007, and for the recommendation of dividend, if any.8 Jun · Meeting
Notice of Extra ordinary General Meeting to be held on June 29, 2007. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
May 2007
24 May · Board meeting
The Board of Directors of the Company at its meeting held on 24th May, 2007 has proposed the following subject to satisfactory receipt of all statutory, regulatory, corporate and other approval including shareholders at their Meeting, as may be acquired. 1) Issue up to 12,00,000 Convertible Warrants on preferential basis to a) Promoters and Promoters Group, b) Directors of the Company, c) Directors of the Subsidiaries, d) Employees of the Company. 2) Issue up to 12,00,000 Equity shares on preferential basis to Strategic Investors: The above issue of Securities (1&2) is being made on preferential basis at an approximate price of Rs.360/- per share / warrant (face value of Rs.10/- and premium Rs.350/- per share/warrant) which is in accordance with the "Guidelines for Preferential Issues" prescribed under SEBI (Disclosure and Investors Protection) Guidelines, 200017 May · Board meeting
Inter alia to consider the following: 1) To consider issue of warrants to promoters and promoters Group. 2) To consider issue securities on preferential basis to strategic investors. 3) To Consider Employees Stock Option Scheme for Employees of the Company and for the subsidiaries/Group Companies present and future.14 May · E-mail ID for Investor Complaints
An e mail "[email protected]" is designated exclusively for the purpose of registering complaints by investors, which would also be displayed prominently as per the newly inserted clause for creating investors awareness.
Apr 2007
26 Apr · Business
The Company has signed purchase agreements to acquire Medical Equipment Companies in India namely Devon Innovations Private limited and Ormed Medical Technology Limited. The Companies manufacture products like Catheters, Stone graspers, Stone Baskets, Dilator Sets etc, for different specialized applications mainly in the areas of Urology, Gastroenterology and Gynaecology. Devon Innovations manufacture Catheters and allied products for various medical segments and Ormed deals in Orthopaedic Prosthesis & Surgical Disposables. Both Companies are ISO 9001 Certified Manufacturing Companies. Devon Products have the CE Mark also. The acquisition of these companies will help Opto to extend their penetration in India and also in the International Health Care market. Opto has already entered the Cardiology Speciality successfully. This acquisition will not only give a synergy in Manufacture and Marketing its Cardiac Stents but also give Opto presence with products in the specialities of Urology, Gastroenterology and Orthopaedics in the domestic and International market.10 Apr · Results
We intend to announce the audited results of the Company for the financial year ended 31st March, 2007 on or before 30th June, 2007. In view of this, we request to exempt us from announcing the Un-audited results.
Mar 2007
15 Mar · Management
Mrs. Rose Chintamani, Company Secretary has resigned and Mr. R. Vijayendra is now appointed as Company Secretary with effect from 2nd February 2007. Mr. R. Vijayendra, is also designated as Compliance Officer
Feb 2007
20 Feb · Miscellaneous
Eurocor GmbH the Company's wholly owned subsidiary has launched its revolutionary product - DIOR, a pacllitaxel-eluting balloon dilation catheter used in PTCA (percutaneous transluminal coronary angioplasty) procedures. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.9 Feb · Miscellaneous
Eurocor GmbH the Company's wholly owned subsidiary has received the CE Mark Approval for its "DIOR" a Paclitaxel Coated Ballon Catheter, used in treatment of Coronary in-stent restonosis. We are the first company in the world to have obtained CE for a Paclitaxel Coated Ballon Catheter. In March 2006 Eurocor Gmbh obtained CE certification for their Drug Eluting Stent TAXCOR, and in May 2006, for its Amadeus Supercross coronary dilation catheters used in vascular coronary perfusion and also for their new range of PTCA guide wires branded E-WIRE for interventional use. With this CE mark for DIOR all the products of Europe are now CE Certified, allowing the company to market all its products in the European Union as well as in Fareast, Middle East, Latin America and Asia
Jan 2007
23 Jan · Utilisation of Funds
Utilisation of Public Issue Proceeds :- Rs. in Lakhs. (1) Project cost :-Upgradation of Research & Development facility; Projected in Prospectus ( Rs. in lakhs ) :- 1938.00; Utilisation as at 31st December 2006( Rs. in lakhs ) :- 95.34; (2) Project cost :- Cost of Upgrading Infrastructure and for modernizing and acquisition of additional plant & machinery; Projected in Prospectus( Rs. in lakhs ) :- 1635.00; Utilisation as at 31st December 2006( Rs. in lakhs ) :- 848.28; (3) Project cost :- Investment in Mediaid Inc for establishing marketing offices; Projected in Prospectus( Rs. in lakhs ) :- 750.00; Utilisation as at 31st December 2006( Rs. in lakhs ) :- 558.84; (4) Project cost :- Acquisition of Eurocor Gmbh; Projected in Prospectus( Rs. in lakhs ) :- 2721.00; Utilisation as at 31st December 2006( Rs. in lakhs ) :- 2695.62; (5) Project cost :- Additional Working Capital Requirment; Projected in Prospectus ( Rs. in lakhs ):- 2250.00; Utilisation as at 31st December 2006( Rs. in lakhs ) :- 3020.48; (6) Project cost :- Cash & Bank Balances & Advances; Utilisation as at 31st December 2006( Rs. in lakhs ) :- 2844.07; (7) Project cost :- Issue Expenses; Projected in Prospectus( Rs. in lakhs ) :- 706.00; Utilisation as at 31st December 2006( Rs. in lakhs ) :- 737.37. Total :- Projected in Prospectus( Rs. in lakhs ) :- 10000.00; Utilisation as at 31st December 2006 :- ( Rs. in lakhs )10800.00. Means of Finance :- (1) Equity share capital; Projected in Prospectus( Rs. in lakhs ) :- 400.00; Utilisation as at 31st December 2006( Rs. in lakhs ) :- 400.00. (2) Share Premium; Projected in Prospectus( Rs. in lakhs ) :- 9600.00; Utilisation as at 31st December 2006( Rs. in lakhs ) :- 10400.00. Total :- Projected in Prospectus( Rs. in lakhs ) :- 10000.00; Utilisation as at 31st December 2006( Rs. in lakhs ) :- 10800.00.16 Jan · Board meeting
Meeting on 23 Jan 2007: “Unaudited Financial Results for the quarter ended Dec 31, 06”